Core Viewpoint - High-yielding dividend healthcare stocks are positioned as attractive investment options for investors seeking passive income, especially with the potential for interest rate cuts on the horizon [2]. Group 1: Investment Rationale - The healthcare sector is characterized by aging populations, recession resilience, and continuous innovation, making it a structurally sound long-term growth area [6]. - The global population over 65 is expected to double in the coming decades, driving sustained demand for medical services and products [8]. - Technological advancements in areas such as gene therapy and AI diagnostics are creating new revenue streams for healthcare companies [5]. Group 2: Company Highlights - **Bristol-Myers Squibb (NYSE: BMY)**: A biopharmaceutical company with a reliable 4.10% dividend, focusing on transformative medicines across various therapeutic areas [9]. - **Healthpeak Properties (NYSE: DOC)**: A REIT investing in healthcare real estate, offering a solid 7.01% dividend and rated highly by analysts [13]. - **Merck (NYSE: MRK)**: A major player in the healthcare industry with a 2.79% dividend, known for its consistent dividend growth over 15 years [16]. - **Pfizer (NYSE: PFE)**: Offers a 6.46% dividend, with strong growth potential from non-COVID products and a promising GLP-1 product launch [21][24]. - **Sanofi (NYSE: SNY)**: A France-based healthcare company with a 4.93% dividend, focusing on patient needs and therapeutic solutions [25].

Core Insights - Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2025 financial results on March 24, 2026, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss the financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity, and has received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the name PEDMARQSI [3] Licensing and Market Presence - In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently available in the U.K. and Germany [4] Regulatory Status and Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents for PEDMARK that extend protection until 2039 in both the U.S. and internationally [5]

Core Insights - The article discusses three growth ETFs that are recommended for investment in 2026, emphasizing their potential to help investors build seven-figure portfolios over time. Group 1: Invesco QQQ Trust (QQQ) - QQQ has returned 459% over the past decade, with a 0.18% expense ratio, focusing 49% on information technology and holding major companies like Nvidia (9%), Apple (7.5%), and Microsoft (5.9%) [1][10][11] - The fund's one-year return is 25%, but it is down about 2% year-to-date in 2026, highlighting the volatility associated with tech concentration [10][11] - QQQ's significant assets amount to $395 billion, providing institutional-grade liquidity [11] Group 2: Vanguard Growth ETF (VUG) - VUG charges a low expense ratio of 0.03% and has returned 81% over the past five years, with a portfolio turnover of just 12% [1][14][15] - The fund includes a diverse range of companies, such as Eli Lilly (2.7%), Visa, and Mastercard, which are not present in QQQ due to its Nasdaq-only focus [12][13] - VUG has $335.9 billion in assets and has shown resilience across multiple market cycles since its inception in 2004 [14] Group 3: Schwab U.S. Large-Cap Growth ETF (SCHG) - SCHG applies a multi-factor growth screen with a cost of 0.04%, and has a ten-year return of 400% and a one-year return of 19% [1][20] - The fund's sector allocation includes 44% in information technology, 8.8% in healthcare, and 7.1% in financials, providing a more balanced exposure compared to QQQ and VUG [18][20] - SCHG has $50 billion in assets under management, making it smaller than QQQ and VUG but still liquid [20] Group 4: Investment Strategy and Considerations - Each ETF offers a different approach to growth investing: QQQ focuses on tech and AI, VUG provides broader exposure at a low cost, and SCHG emphasizes earnings quality across various sectors [21][22] - Investors should consider their existing portfolio and risk tolerance when choosing among these funds [22]

Core Viewpoint - Nutriband Inc. has secured an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products, and mosquito repellent patches, following the approval from the Costa Rica Ministry of Health for the import and sale of its Kinesiology Tapes [1][2]. Group 1: Distribution Agreement and Regulatory Approval - The Costa Rica Ministry of Health has approved Nutriband's Kinesiology Tapes for import and sale, enabling the company to expand its market presence in Costa Rica [1]. - Innomedica CCB, as the exclusive distribution partner, managed and financed the regulatory approval process, indicating a strong partnership for market entry [1]. Group 2: Marketing and Product Development - Nutriband plans to enhance marketing efforts for its Kinesiology products and mosquito repellent patches following the recent regulatory approval [2]. - The company is focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4]. Group 3: AVERSA™ Technology - AVERSA™ technology is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, improving the safety profile of transdermal drugs [3]. - The technology is protected by a broad intellectual property portfolio with patents granted in multiple countries, including the United States, Europe, and Japan, enhancing its competitive position in the market [3].

Core Insights - Harrow has announced that three scientific abstracts related to its products VEVYE and ILEVRO have been accepted for presentation at the ASCRS 2026 Annual Meeting, highlighting the company's commitment to advancing treatment options for ophthalmic diseases [1][2]. Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products for various eye conditions, including dry eye disease, cataracts, and glaucoma [4]. Research Presentation Details - The abstracts will be presented in specific sessions at the ASCRS Annual Meeting, focusing on ocular surface disease and medications related to cataract surgery [2]. - The presentations include a post-hoc analysis of ILEVRO's effectiveness in reducing visual acuity loss associated with cataract surgery and real-world treatment patterns for VEVYE in dry eye disease [6]. Commitment to Evidence-Based Treatment - The acceptance of these abstracts underscores Harrow's ongoing commitment to evidence-based treatment options for ophthalmic diseases, particularly in addressing complications from cataract surgery and dry eye disease [2].

Core Viewpoint - XORTX Therapeutics Inc. is proposing three new director nominees for election to its board of directors during the upcoming annual and special meeting of shareholders, which is a condition for a significant financing initiative the company is currently negotiating [1][2]. Group 1: New Director Nominees - George Scorsis has over 20 years of leadership experience in regulated sectors, previously serving as President of Red Bull Canada and leading Mettrum Health Corp. to a $430 million acquisition by Canopy Growth Corp. [3] - Richard Grieve is the Chief Operating Officer at Bardel Entertainment Inc., with a strong background in finance and operational strategies within media production [4]. - Mika Grasso is an Investment Manager at a family office, with prior experience at Zions Capital Markets, Paulson Investment Company, and Goldman Sachs [5]. Group 2: Financing Initiative - The addition of the new nominees to the board is a condition for the completion of a significant financing initiative, which is subject to the approval of the TSXV Venture Exchange [2]. - If the financing is not completed, the new nominees will resign from the board, and the company will fill those vacancies in due course [2]. Group 3: Company Overview - XORTX Therapeutics is focused on developing innovative therapies for gout and progressive kidney disease, with three clinically advanced products in development [10][11]. - The lead program, XRx-026, targets gout, while XRx-008 is for ADPKD, and XRx-101 addresses acute kidney injury associated with respiratory virus infections [10].

Core Viewpoint - Bristol Myers Squibb is positioned as a defensive stock in a volatile market, demonstrating resilience with a year-to-date gain while the S&P 500 has declined [1] Financial Performance - Current stock price is $59.61 with a market capitalization of $122 billion [2] - The company has a gross margin of 65.89% and a dividend yield of 4.17% [2][7] - Revenue from the growth portfolio is projected to account for approximately 55% of total revenue in 2025, up from 47% the previous year [3] Patent Challenges - The company faces a patent cliff with its top-selling drugs, Eliquis and Opdivo, losing patent exclusivity in 2028, while Revlimid is already facing generic competition [2] Pipeline and Growth Strategy - Bristol Myers Squibb has a robust pipeline, expecting to report results from pivotal clinical studies for 28 programs by the end of 2028, with half being new therapies [4] - The company has made strategic acquisitions, including Orbital Therapeutics for CAR-T therapy and Karuna Therapeutics for the neuroscience drug KarXT [5] Dividend History - Bristol Myers Squibb has a strong dividend history, having paid dividends for 94 consecutive years and increased its dividend for 17 straight years [7] Market Resilience - The company's business model is expected to remain stable during potential market downturns caused by geopolitical crises, AI bubbles, or economic declines, as demand for its therapies is likely to persist [8][9]

Core Insights - Orion Corporation and CMI - Martti Ahtisaari Peace Foundation have formed a strategic partnership aimed at promoting peace through health and well-being [1][3] - The partnership emphasizes the importance of societal health as a foundation for lasting peace, advocating for peace as a continuous practice rather than a reaction to crises [3][4] Company Overview: Orion Pharma - Orion Pharma is a Nordic pharmaceutical company with over a century of experience, focusing on developing and marketing human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients [8] - The company reported net sales of EUR 1,890 million in 2025 and employs approximately 4,000 professionals globally [8] Partnership Details - A key initiative of the partnership is the "Prescriptions for Peace" video series, which consists of nine episodes that highlight essential conditions for sustainable peace, such as trust, dialogue, and inclusion [5][6] - The series aims to encourage reflection on peacebuilding, presenting it as a conscious choice and a long-term commitment rather than a quick fix [6][7] About CMI - CMI is an independent, non-profit organization founded by Nobel Peace Prize laureate Martti Ahtisaari, dedicated to conflict resolution and peace mediation [9] - The organization has been involved in over 50 peace processes worldwide, positioning itself as a leading entity in the field of peace mediation [9]

Core Insights - The FDA has granted Breakthrough Therapy designation to venglustat for treating neurological manifestations of type 3 Gaucher disease (GD3), highlighting its potential in addressing a significant unmet medical need [1][5][6] Group 1: Product and Clinical Data - Venglustat is an investigational oral glucosylceramide synthase inhibitor (GCSi) designed to reduce the accumulation of glycosphingolipids (GSLs) in the central nervous system (CNS) [4][8] - The LEAP2MONO phase 3 study showed that patients receiving venglustat had statistically significant improvements in neurological symptoms compared to those receiving enzyme replacement therapy (ERT), with a p-value of 0.007 [2][7] - Common adverse events reported in the study included headache (14.3% for venglustat vs. 18.2% for ERT), nausea (14.3% vs. 4.5%), spleen enlargement (14.3% vs. 0%), and diarrhea (14.3% vs. 0%) [2] Group 2: Disease Background - Gaucher disease (GD) is a rare inherited lysosomal storage disorder caused by a deficiency of glucocerebrosidase, leading to GSL accumulation in various organs [3] - GD3 is characterized by slower progression and variable symptom severity, with neurological symptoms being a significant concern [3][4] Group 3: Regulatory and Future Plans - Sanofi plans to pursue global regulatory filings for venglustat in GD3 during 2026, following its previous fast-track and orphan designations from the FDA [5] - The Breakthrough Therapy designation aims to expedite the development and review of medicines targeting serious conditions, requiring preliminary clinical evidence of substantial improvement over existing treatments [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - The lawsuit alleges that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the regulatory prospects of its INO-3107 Biologics License Application [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4].